Cargando…
Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
BACKGROUND: Around 30% of patients with inflammatory bowel disease (IBD) are refractory to current IBD drugs or relapse over time. Novel treatments are called for, and low dose Naltrexone (LDN) may provide a safe, easily accessible alternative treatment option for these patients. We investigated the...
Autores principales: | Lie, Mitchell R. K. L., van der Giessen, Janine, Fuhler, Gwenny M., de Lima, Alison, Peppelenbosch, Maikel P., van der Ent, Cokkie, van der Woude, C. Janneke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845217/ https://www.ncbi.nlm.nih.gov/pubmed/29523156 http://dx.doi.org/10.1186/s12967-018-1427-5 |
Ejemplares similares
-
A Direct Effect of Sex Hormones on Epithelial Barrier Function in Inflammatory Bowel Disease Models
por: van der Giessen, Janine, et al.
Publicado: (2019) -
Modulatory Effects of Pregnancy on Inflammatory Bowel Disease
por: van der Giessen, Janine, et al.
Publicado: (2019) -
Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn’s disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study
por: Paulides, Emma, et al.
Publicado: (2022) -
Modulation of cytokine patterns and microbiome during pregnancy in IBD
por: van der Giessen, Janine, et al.
Publicado: (2020) -
Peripheral Neutrophil Functions and Cell Signalling in Crohn`s Disease
por: Somasundaram, Rajesh, et al.
Publicado: (2013)